Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2019-01-25 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholder equity, specifically an increase in shareholding by a particular shareholder. It details the number of shares acquired, the dates of acquisition, and the percentage of total shares held before and after the transaction. There is no indication of a full financial report, audit, or management discussion. The document is a formal announcement of a change in major shareholding levels, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on this equity change, confirming it is not a full report or other filing type.
2019-01-25 Chinese
2018年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a 2018 annual performance forecast (业绩预告) for the company Quantum Hi-Tech (量子高科). It provides estimated net profit figures for the full year 2018 and compares them to the prior year. It explicitly states that the forecast has not been audited and that detailed actual results will be disclosed in the 2018 annual report. The document is short (817 characters) and serves as a preliminary earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements or substantive analysis. Therefore, the correct classification is Earnings Release (ER).
2019-01-25 Chinese
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company Quantum Hi-Tech (China) Biological Co., Ltd. It details the convening of the fourth board's sixth meeting, the attendance, and the approval of a specific investment change proposal. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results from a shareholder meeting, and no other report publication. The content is focused on board decisions and management resolutions. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive board decision announcement.
2019-01-17 Chinese
关于投资医药创新产业基金的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about a change in the investment entity for a pharmaceutical innovation industry fund. It details the background, the change in the investment subject from one subsidiary to another, and states that this change does not constitute a major asset restructuring and does not require shareholder approval. The document is relatively short (1415 characters) and focuses on a corporate transaction update rather than financial results, management changes, or regulatory filings. It is not a full financial report, audit report, or earnings release. It is also not a voting result or a proxy statement. The content fits best with a Capital/Financing Update (CAP) as it relates to investment and fund participation changes.
2019-01-17 Chinese
第四届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company Quantum Hi-Tech (量子高科). It details the approval of a change in the investment entity for a pharmaceutical innovation fund, including voting results. The document is short (655 characters) and focuses on a board meeting decision rather than financial results or detailed reports. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2019-01-17 Chinese
关于对控股孙公司增资并引入战略投资者的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the capital increase in a subsidiary company and the introduction of a strategic investor. It details the investment amounts, changes in shareholding structure, company background, and the purpose and risks of the investment. The document is relatively short (3012 characters) and focuses on a specific financing event rather than providing comprehensive financial statements or performance data. It does not contain full financial reports or detailed financial analysis but rather an update on financing activities and corporate structure changes related to capital injection. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2019-01-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.